Tüdőrák: vizsgálatok itt: Kanada

156 trials · From ClinicalTrials.gov, checked 2026. november 13.. Ask the study team whether a trial fits you.

• 3. fázisTaking people
  Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

  Where

  Kingston, Kitchener, Montreal, Trois-Rivières

  Életkor

  18 év and over

  People

  851 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06422143 · EU 2023-510128-66-00
• 3. fázisTaking people
  A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

  Where

  Greater Sudbury, Hamilton, Montreal, Saint John, Sault Ste. Marie, Sydney

  Életkor

  18 év and over

  People

  1160 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT06692738 · EU 2024-514281-39-00
• 3. fázisTaking people
  Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

  Where

  Chicoutimi, Lévis, London, Montreal, Newmarket, Oshawa, Rimouski, Saskatoon, St. John's, Toronto, Trois-Rivières, Vancouver, Winnipeg

  Életkor

  18 év and over

  People

  675 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT06357533 · EU 2023-505077-32-00
• 3. fázisTaking people
  A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

  Where

  Abbotsford British Columbia, Greater Sudbury, Hamilton, Kingston, Montreal, Saint-Jérôme, Saint John, Sault Ste. Marie, Sydney

  Életkor

  18 év and over

  People

  1160 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT06627647 · EU 2024-515008-38-00
• 3. fázisTaking people
  A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  Where

  Montreal

  Életkor

  18 év and over

  People

  630 worldwide

  Run by

  Mirati Therapeutics Inc.

  See details and how to joinNCT06875310 · EU 2024-515698-85-00
• 2. fázisTaking people
  A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  Where

  Edmonton, Toronto, Vancouver

  Életkor

  18 év and over

  People

  740 worldwide

  Run by

  Daiichi Sankyo

  See details and how to joinNCT06172478 · EU 2023-507641-29-00
• No phaseTaking people
  Lungs on Fire: Wildfire Smoke, Incident Diseases, Susceptible Populations, and Community Values in Canada

  Where

  Vancouver

  Életkor

  19 év to 80 év

  People

  24

  Run by

  University of British Columbia

  See details and how to joinNCT07536178
• 3. fázisTaking people
  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  Where

  Halifax, Oshawa, Ottawa, Prince George, Toronto

  Életkor

  18 év and over

  People

  750 worldwide

  Run by

  Bristol-Myers Squibb

  See details and how to joinNCT07361510 · EU 2025-523586-18-00
• No phaseTaking people
  Dietary Intervention for NSCLC Patients Treated With ICI

  Where

  Montreal

  Életkor

  18 év and over

  People

  80

  Run by

  Centre hospitalier de l'Université de Montréal (CHUM)

  See details and how to joinNCT05805319
• 2. fázisTaking people
  Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

  Where

  Edmonton, Montreal, Winnipeg

  Életkor

  18 év to 95 év

  People

  630 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT05061550 · EU 2023-508852-21-00
• 3. fázisTaking people
  Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

  Where

  Barrie, Hamilton, Montreal, Rimouski, Toronto

  Életkor

  18 év and over

  People

  695 worldwide

  Run by

  Gilead Sciences

  See details and how to joinNCT06801834
• No phaseTaking people
  CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease

  Where

  Vancouver

  Életkor

  18 év and over

  People

  10

  Run by

  British Columbia Cancer Agency

  See details and how to joinNCT05257967
• 2. fázisTaking people
  A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

  Where

  Toronto

  Életkor

  18 év and over

  People

  278 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT07098338 · EU 2025-524843-11-00
• 1/2. fázisTaking people
  A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

  Where

  Calgary, Montreal, Ottawa, Toronto, Vancouver

  Életkor

  18 év and over

  People

  460 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT05123482 · EU 2022-502759-70-01
• 3. fázisTaking people
  Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

  Where

  Toronto

  Életkor

  18 év to 100 év

  People

  96 worldwide

  Run by

  InSightec

  See details and how to joinNCT05317858
• 3. fázisTaking people
  A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

  Where

  Brampton, Edmonton, London, Toronto

  Életkor

  18 év and over

  People

  360 worldwide

  Run by

  Taiho Oncology, Inc.

  See details and how to joinNCT07128199 · EU 2025-521775-31-00
• 2. fázisNot yet taking people in Kanada
  A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)

  Where

  Calgary, Montreal, Oshawa

  Életkor

  18 év and over

  People

  80 worldwide

  Run by

  Bristol-Myers Squibb

  See details and how to joinNCT07871214
• 1. fázisTaking people
  Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

  Where

  Montreal

  Életkor

  18 év and over

  People

  180 worldwide

  Run by

  Novartis Pharmaceuticals

  See details and how to joinNCT07261631
• 3. fázisTaking people
  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  Where

  Calgary, Chicoutimi, Edmonton, Greenfield Park, London, Montreal, Sherbrooke, Toronto, Windsor

  Életkor

  18 év and over

  People

  1410 worldwide

  Run by

  Pfizer

  See details and how to joinNCT07222566 · EU 2025-523461-17-01
• 1. fázisTaking people
  Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

  Where

  Montreal, Toronto

  Életkor

  18 év and over

  People

  473 worldwide

  Run by

  Bicara Therapeutics

  See details and how to joinNCT04429542
• 2. fázisTaking people
  A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

  Where

  Brampton

  Életkor

  18 év and over

  People

  220 worldwide

  Run by

  Taiho Oncology, Inc.

  See details and how to joinNCT05967689
• 1/2. fázisTaking people
  Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

  Where

  Edmonton, London, Montreal, Toronto

  Életkor

  18 év to 130 év

  People

  622 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT05797168 · EU 2022-502576-23-00
• 2/3. fázisTaking people
  A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

  Where

  Ottawa, Toronto

  Életkor

  18 év and over

  People

  854 worldwide

  Run by

  AbbVie

  See details and how to joinNCT07005102
• 2/3. fázisTaking people
  A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

  Where

  Brampton

  Életkor

  18 év and over

  People

  490 worldwide

  Run by

  AbbVie

  See details and how to joinNCT07155187 · EU 2025-521124-29-00
• 3. fázisTaking people
  Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

  Where

  Toronto

  Életkor

  18 év and over

  People

  450 worldwide

  Run by

  Nuvalent Inc.

  See details and how to joinNCT06765109 · EU 2024-517553-26-00